Immunogenicity, efficacy, and safety of CoronaVac and Pfizer/BioNTech mRNA vaccines in patients with psoriasis receiving systemic therapies: A prospective cohort study

•mRNA SARS-CoV-2 vaccines in psoriasis patients provide remarkable immunogenicity regardless of the biological treatment.•Inactivated SARS-CoV-2 vaccines develop significantly lower immune response than mRNA vaccines in psoriasis patients using biologicals and methotrexate.•Antispike and neutralisin...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Vaccine 2023-06, Vol.41 (29), p.4287-4294
Hauptverfasser:	Ergun, Tulin, Hosgoren Tekin, Selcen, Apti Sengun, Ozlem, Akin Cakici, Ozlem, Seckin, Dilek, Adiay, Cumhur, Enul, Hakan, Yilmaz, Seval, Ay, Pinar, Haklar, Goncagul, Sili, Uluhan
Format:	Artikel
Sprache:	eng
Schlagworte:	anti-IL17 Antibodies Antibodies, Neutralizing Antibodies, Viral antiTNF Biological Factors Biologics Body mass index Cohort analysis cohort studies COVID-19 COVID-19 - prevention & control COVID-19 infection COVID-19 vaccines COVID-19 Vaccines - adverse effects Deactivation Disease transmission Drug dosages Drug-Related Side Effects and Adverse Reactions Humans Immune response Immune system Immunogenicity Immunogenicity, Vaccine inactivated vaccines Infections Infliximab live vaccines Methotrexate Monoclonal antibodies mRNA mRNA vaccines Plasma Prospective Studies Proteins Psoriasis Psoriasis - drug therapy Rheumatic diseases SARS-CoV-2 Serology Severe acute respiratory syndrome coronavirus 2 Side effects Skin diseases Tumor necrosis factor-α Vaccination Vaccines Vaccines, Inactivated
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!